I suspect the issue may be, that MSB sees mileage in impressing...

I suspect the issue may be, that MSB sees mileage in impressing regulators with multiple PhII trials, across multiple disease types [ie, diabetes and RA]......and aiming for lumping all that data in and saying....."can we get some type of breakthrough/early approval please". Time will tell....but I think RA is just about complete with its PhII now and D is done....so a decision point has been arrived at. MPC-300-IV has heaps of potential, across many disease targets, I think the Prof has said it's the candidate he personally sees the most potential in.

Perhaps it's a question we MSB followers should seek some clarification on, as we move toward the reporting season - where's MPC-300-IV at and where to for it over the next couple of years or so?